Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections

Blood

Volumn 123, Issue 21, 2014, Pages 3263-3268

  Shah, Dimpy P ^a   Ghantoji, Shashank S ^a   Ariza Heredia, Ella J ^a   Shah, Jharna N ^b   El Taoum, Katia K ^a   Shah, Pankil K ^c   Nesher, Lior ^a   Hosing, Chitra ^a   Rondon, Gabriela ^a   Champlin, Richard E ^a   Chemaly, Roy F ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PALIVIZUMAB; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CHILD; DISEASE COURSE; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNODEFICIENCY SCORING SYSTEM; INFECTION RISK; INTENSIVE CARE UNIT; LOW RISK POPULATION; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; NEUTROPENIA; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS INFECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK REDUCTION; SCORING SYSTEM; SINGLE DRUG DOSE; SURVIVAL RATE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INCIDENCE; MALE; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901462680     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-541359     Document Type: Article

References (25)

1. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117(10): 2755-2763.
2. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68(8):1872-1880.
3. Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11(10):781-796. (Pubitemid 41403760)
4. Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica. 2009;94(8):1101-1108.
5. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006;85(5):278-287. (Pubitemid 44401460)
6. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant. 2001;7(Suppl): 5S-7S. (Pubitemid 33734761)
7. Nichols WG, Gooley T, Boeckh M. Communityacquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7(Suppl):11S-15S. (Pubitemid 33734763)
8. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22(5):778-782. (Pubitemid 26255593)
9. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 2000;25(7):751-755. (Pubitemid 30189516)
10. Soldatou A, Davies EG. Respiratory virus infections in the immunocompromised host. Paediatr Respir Rev. 2003;4(3):193-204. (Pubitemid 36987176)
11. Crooks BNA, Taylor CE, Turner AJL, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant. 2000;26(10):1097-1102.
12. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008; 46(3):402-412. (Pubitemid 351263523)
13. Lewinsohn DM, Bowden RA, Mattson D, Crawford SW. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother. 1996;40(11):2555-2557. (Pubitemid 26367642)
14. Sparrelid E, Ljungman P, Ekelöf-Andström E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997;19(9):905-908. (Pubitemid 27217657)
15. Schleuning M, Buxbaum-Conradi H, Jäger G, Kolb HJ. Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants. Hematol J. 2004;5(2):135-144. (Pubitemid 38519263)
16. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized doubleblind study. N Engl J Med. 1983;308(24): 1443-1447. (Pubitemid 13103444)
17. Hertz MI, Englund JA, Snover D, Bitterman PB, McGlave PB. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine (Baltimore). 1989;68(5):269-281. (Pubitemid 19251931)
18. Torres HA, Aguilera EA, Mattiuzzi GN, et al. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica. 2007;92(9):1216-1223. (Pubitemid 350144180)
19. Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001; 22(2):102-110. (Pubitemid 32289446)
20. Shah DP, Ghantoji SS, Mulanovich VE, Ariza- Heredia EJ, Chemaly RF. Management of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res. 2012;2(4): 203-218.
21. Boeckh MJ, Gooley T, Englund J, et al. Respiratory syncytial virus (RSV) infection in hematopoietic stem cell transplant (HCT) recipients: risk factors for acquisition and lower respiratory tract disease, and impact on mortality [abstract]. Blood. 2004;104(11). Abstract 187.
22. Raboni SM, Nogueira MB, Tsuchiya LR, et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation. 2003;76(1): 142-146. (Pubitemid 36880830)
23. Boeckh M, Englund J, Li Y, et al; NIAID Collaborative Antiviral Study Group. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44(2):245-249. (Pubitemid 46079989)
24. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195-1204. [Epub ahead of print]
25. Granwehr BP, Chemaly RF, Kontoyiannis DP. Fungal and Viral infections in Cancer Patients. In: Kantarjian HM, Wolff RA, Koller CA, eds. MD Anderson Manual of Medical Oncology. United States: McGraw-Hill Professional; 2011: 1205-1234.